Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Rheumatology
•
Rheumatoid Arthritis
•
Gastroenterology
•
General Hepatology
How you do approach treatment for a patient with active seropositive RA (+RF/+CCP) who is receiving treatment for Hepatitis C?
Related Questions
Do you avoid JAK inhibitors in patients with a history of liver disease including NAFLD or cirrhosis?
How would you manage a patient with highly active ankylosing spondylitis, iritis and Crohn’s, controlled with weekly adalimumab with co-morbid IgG4RD and intolerance of azathioprine due to elevated LFTs?
How do you approach managing nausea and GI side effects when initiating methotrexate?
Is there a risk of hepatitis C activation with rituximab in a patient who has a history of HCV treated with antivirals and who is in sustained viral response?
What approaches can we take to initiate therapy and improve survival rates in patients with HLH?
Do you feel comfortable using Jak inhibitors in patients with a strong family history of CAD, but no other risk factors?
Does hepatitis B vaccination reduce the risk of HBV reactivation associated with immunosuppressive therapy?
Do you avoid terlipressin for patients with hepatorenal syndrome who have a serum sodium level less than 125 mEq/L?
Is there a role for nitazoxanide for treatment of norovirus gastroenteritis in immunocompromised patients?
How would you manage a solitary unresectable liver metastasis?
